The International Society for the Advancement of Spine Surgery issued coverage recommendation for Mainstay Medical’s ReActiv8 neurostimulation, the medtech company said Dec. 11.
ISASS’ statement affirms support for coverage by payers of implantable restorative neurostimulation, according to a news release. The organization’s statement cite growing clinical evidence supporting ReActiv8, along with recent developments in diagnostic coding and reimbursement pathways.
Key developments in restorative neurostimulation include one- and five-year trial results supporting ReActiv8 and the introduction of ICD-10 code M62.85. Additionally payers including Anthem Blue Cross Blue Shield have already issued favorable coverage for ReActiv8.
“Multifidus dysfunction defines a motor-control–deficient back-pain phenotype,” Morgan Lorio, MD, ISASS past president and chair emeritus of ISASS’ coding and reimbursement task force, told Becker’s. “Restorative neurostimulation restores motor control progressively and durably, a true disease-modifying, motion-preserving therapy. Aligning with ISASS’ Spines in Motion vision, it brings functional restoration back to the center of spine care.”
Read the full statement here.
